Sanjiv.Parant.

Which are the latest news on Sanjiv.Parant.?

Why is Sanjivani Paranteral Ltd falling/rising?

As of 05-Sep, Sanjivani Paranteral Ltd's stock price is Rs 189.60, down 0.45%, reflecting a downward trend with a total decline of 3.52% over the last two days. Despite recent short-term gains, the stock has significant year-to-date and annual losses, coupled with declining investor participation, contributing to its current price drop.

As of 05-Sep, Sanjivani Paranteral Ltd's stock price is currently at Rs 189.60, reflecting a decrease of Rs 0.85, or 0.45%. The stock has been on a downward trend, having fallen for the last two consecutive days, resulting in a total decline of 3.52% during this period. Additionally, the stock has underperformed its sector by 1.1% today.<BR><BR>Despite a recent positive performance over the past week and month, where the stock gained 4.03% and 18.80% respectively, it has experienced significant declines year-to-date and over the past year, with losses of 18.12% and 24.10%. This suggests that while there have been short-term gains, the overall longer-term performance has been negative.<BR><BR>Investor participation appears to be declining, as evidenced by a substantial drop in delivery volume, which fell by 93.66% compared to the 5-day average. This lack of investor engagement may contribute to the stock's current downward movement. Furthermore, although the stock is trading above its 50-day, 100-day, and 200-day moving averages, it is below its 5-day and 20-day moving averages, indicating a potential shift in momentum.<BR><BR>In summary, the combination of recent consecutive declines, reduced investor participation, and overall negative long-term performance are key factors contributing to the current fall in Sanjivani Paranteral Ltd's stock price.

Who are in the management team of Sanjiv.Parant.?

The management team of Sanjiv.Parant. includes Ashwin Khemka (Chairman & Managing Director), Mrunmai M Sarvankar, Shrenikkumar P Solanki, and Monika Singhania (Independent Directors), Srivardhan Ashwani Khemka (Director), and Ritu Puglia (Company Secretary & Compliance Officer).

The management team of Sanjiv.Parant. includes the following individuals:<BR><BR>1. Ashwin Khemka - Chairman & Managing Director<BR>2. Mrunmai M Sarvankar - Independent Director<BR>3. Shrenikkumar P Solanki - Independent Director<BR>4. Monika Singhania - Independent Director<BR>5. Srivardhan Ashwani Khemka - Director<BR>6. Ritu Puglia - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its management, feel free to ask!

What does Sanjiv.Parant. do?

Sanjivani Paranteral Ltd is a WHO-GMP certified pharmaceutical company specializing in injectables and oral solids, with a market cap of INR 228 Cr and reported net sales of 24 Cr and net profit of 2 Cr for June 2026. Key metrics include a P/E of 32.00 and a dividend yield of 0.28%.

Overview: <BR>Sanjivani Paranteral Ltd is a WHO-GMP certified pharmaceutical company specializing in the manufacturing of injectables and oral solids, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Sanjivani Paranteral Ltd was incorporated as a public limited company in October. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 24 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Jun 2026) <BR>Market cap: INR 228 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.28% <BR>Debt Equity: 0.27 <BR>Return on Equity: 13.89% <BR>Price to Book: 4.61 <BR><BR>Contact Details: <BR>Address: 205 P N Khotari Indl Estate, LBS Marg Bhandup (West) Mumbai Maharashtra : 400078 <BR>Tel: 91-22-67290900 <BR>Email: info@sanjivani.co.in <BR>Website: http://www.sanjivani.co.in

Who are the peers of the Sanjiv.Parant.?

Sanjiv.Parant.'s peers include Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda, Natural Capsules, Coral Labs, Oxygenta Pharma, Accretion Pha., and Sat Kartar Life. In terms of management risk, Sanjiv.Parant. has a good rating, with a 1-year return of -24.23%, better than Kerala Ayurveda but worse than Aarey Drugs at 44.47%.

Peers: Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda, Natural Capsules, Sanjiv.Parant., Coral Labs., Oxygenta Pharma, Accretion Pha., Sat Kartar Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sat Kartar Life and Accretion Pha., while Good management risk is found at Sanjiv.Parant. and Accretion Pha. Average management risk is noted at Lyka Labs, Nectar Lifesci., and the rest. Below Average management risk is seen at Aarey Drugs, Kerala Ayurveda, Natural Capsules, and Coral Labs. In terms of Growth, Excellent growth is noted at Accretion Pha. and Good growth at Sanjiv.Parant. and Accretion Pha. Average growth is found at Lyka Labs, Nectar Lifesci., and the rest, while Below Average growth is observed at Aarey Drugs, Kerala Ayurveda, Natural Capsules, and Coral Labs. For Capital Structure, Excellent capital structure is seen at Sanjiv.Parant. and Coral Labs., while Good capital structure is noted at Accretion Pha. and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aarey Drugs at 44.47%, while the lowest is Kerala Ayurveda at -63.87%. Sanjiv.Parant.'s 1-year return is -24.23%, which is better than Kerala Ayurveda but worse than Aarey Drugs. Additionally, Oxygenta Pharma and Kerala Ayurveda have negative six-month returns.

How big is Sanjiv.Parant.?

As of 31st August, Sanjivani Paranteral Ltd has a market capitalization of 228.00 Cr, with Net Sales of 74.61 Cr and a Net Profit of 7.46 Cr reported in the latest four quarters.

As of 31st August, Sanjivani Paranteral Ltd has a market capitalization of 228.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 74.61 Cr and a Net Profit of 7.46 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 48.25 Cr and Total Assets of 87.97 Cr.

Should I buy, sell or hold Sanjivani Paranteral Ltd?

When is the next results date for Sanjivani Paranteral Ltd?

The next results date for Sanjivani Paranteral Ltd is 14 August 2026.

The next results date for Sanjivani Paranteral Ltd is scheduled for 14 August 2026.

Are Sanjivani Paranteral Ltd latest results good or bad?

Sanjivani Paranteral Ltd's latest results are concerning, showing a 74.89% decline in net profit and a 27.34% drop in revenue year-on-year for Q4 FY26, alongside a significant compression in profit margins and a high effective tax rate. Overall, these results indicate serious operational challenges and investor apprehension about the company's future.

The latest results for Sanjivani Paranteral Ltd indicate a challenging situation for the company. In Q4 FY26, the company reported a net profit of ₹0.55 crores, which represents a dramatic decline of 74.89% year-on-year. Revenue also fell significantly, down 27.34% year-on-year to ₹13.21 crores, and experienced a sharp 40.12% decline compared to the previous quarter.<BR><BR>The company's profit after tax (PAT) margin has compressed to 4.16%, down from 12.05% in the same quarter last year, highlighting serious operational issues. Additionally, the effective tax rate surged to an unusually high 54.17%, which has further impacted profitability without clear explanation.<BR><BR>While the company has shown robust growth in revenue for the full year FY25, reaching ₹70 crores, the fourth quarter results raise significant concerns about its operational execution and market demand. The stock has also faced a severe correction, trading significantly below its previous highs, which reflects investor apprehension regarding the sustainability of its business model.<BR><BR>Overall, the latest results can be characterized as bad, with notable declines in both profit and revenue, alongside troubling operational challenges that investors should closely monitor.

Is Sanjiv.Parant. overvalued or undervalued?

As of November 17, 2025, Sanjiv.Parant. is considered very expensive and overvalued due to its high PE ratio of 30.96, price to book value of 6.08, and EV to EBITDA of 23.36, especially in light of its 37.72% decline in stock performance compared to the Sensex's 9.50% gain over the past year.

As of 17 November 2025, the valuation grade for Sanjiv.Parant. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued based on its high PE ratio of 30.96, a price to book value of 6.08, and an EV to EBITDA of 23.36. In comparison to its peers, Sun Pharma has a higher PE ratio of 36.69, while Cipla appears more attractive with a PE of 22.81.<BR><BR>Given these ratios and the overall market context, Sanjiv.Parant.'s valuation seems excessive, particularly when considering its recent stock performance, which has underperformed the Sensex significantly over the past year, with a decline of 37.72% compared to the Sensex's gain of 9.50%. This further reinforces the conclusion that the company is overvalued in its current state.

How has been the historical performance of Sanjiv.Parant.?

Sanjiv.Parant. experienced significant growth from March 2024 to March 2025, with net sales rising to 70.10 Cr from 54.41 Cr, and profit after tax increasing to 8.09 Cr from 6.17 Cr. The company also saw improvements in operating profit and cash flow from operating activities, alongside a rise in total assets and liabilities.

Answer:<BR>The historical performance of Sanjiv.Parant. shows significant growth from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Sanjiv.Parant. reported net sales of 70.10 Cr, an increase from 54.41 Cr in the previous year. Total operating income also rose to 70.10 Cr from 54.41 Cr, while total expenditure increased to 59.75 Cr from 46.17 Cr. The operating profit (PBDIT) grew to 11.57 Cr from 8.76 Cr, reflecting a healthy operating profit margin of 14.76%, slightly down from 15.14%. Profit before tax reached 10.35 Cr, up from 7.57 Cr, leading to a profit after tax of 8.09 Cr compared to 6.17 Cr the prior year. The earnings per share improved to 6.81 from 5.28. On the balance sheet, total assets increased to 78.20 Cr from 43.41 Cr, with total liabilities also rising to 78.20 Cr from 43.41 Cr. Cash flow from operating activities improved to 12.00 Cr from -10.00 Cr, while cash flow from investing activities worsened to -21.00 Cr from -12.00 Cr. Overall, the company demonstrated strong growth in sales and profitability, alongside a notable increase in total assets and liabilities.

What is the technical trend for Sanjiv.Parant.?

As of May 28, 2025, the technical outlook for Sanjiv.Parant. is mildly bearish, with mixed signals from MACD, moving averages, and Bollinger Bands, and a year-to-date decline of 36.13% compared to the Sensex's gain of 5.48%.

As of 28 May 2025, the technical trend for Sanjiv.Parant. has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The daily moving averages also reflect a mildly bearish stance. Bollinger Bands show a mildly bearish trend on the weekly chart but are bullish on the monthly chart, suggesting mixed signals across time frames. The KST is bearish weekly and mildly bearish monthly, further supporting the overall mildly bearish outlook. The stock has underperformed the Sensex in the year-to-date period, with a significant decline of 36.13%, contrasting with the Sensex's gain of 5.48%. Overall, the current technical stance is mildly bearish, with key indicators such as MACD and moving averages driving this view.

Who are the top shareholders of the Sanjiv.Parant.?

The top shareholders of Sanjiv.Parant. are Ashwani Khemka with 27.13%, and Suresh Pukhraj Jain, the highest public shareholder, with 6.63%. Individual investors hold a combined 52.43%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Sanjiv.Parant. include Ashwani Khemka, who holds the largest share at 27.13%. The highest public shareholder is Suresh Pukhraj Jain, with a holding of 6.63%. Additionally, individual investors collectively hold 52.43% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Has Sanjiv.Parant. declared dividend?

No Dividend History Available